<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PROPANTHELINE BROMIDE</span><br/>(proe-pan'the-leen)<br/><span class="topboxtradename">Pro-Banthine, </span><span class="topboxtradename">Propanthel <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antispasmodic</span>; <span class="classification">anticholinergic</span>; <span class="classification">antimuscarinic agent</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>7.5 mg, 15 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Similar to atropine in peripheral effects. Has potent antimuscarinic activity and ganglionic blocking action. Very high doses
         block neurotransmission at myoneural junction.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases motility (smooth muscle tone) in the GI, biliary, and urinary tracts. Results in antispasmodic action.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct in treatment of peptic ulcer, irritable bowel syndrome, pancreatitis, ureteral and urinary bladder spasm. Also used
         prior to radiologic diagnostic procedures to reduce duodenal motility.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C), lactation; narrow angle glaucoma; tachycardia, MI; paralytic ileus, GI obstructive disease; myasthenia
         gravis. Safety in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>CAD, CHF, cardiac arrhythmias; liver disease, ulcerative colitis, hiatus hernia, esophagitis; kidney disease; prostatic hypertrophy;
         glaucoma; debilitated patients; hyperthyroidism; autonomic neuropathy; brain damage; Down's syndrome; spastic disorders.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Irritable Bowel Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg 30 min a.c. and 30 mg h.s. (max: 120 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 7.5 mg 23 times/d a.c. (max: 90 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 3060 min before meals and at bedtime. Advise not to chew tablet; drug is bitter.</li>
<li>Give at least 1 h before or 1 h after an antacid (or antidiarrheal agent).</li>
<li>Store dry powder and tablets at 15°30° C (59°86° F); protect from freezing and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Constipation, dry mouth.</span> <span class="typehead">Special Senses:</span> Blurred vision, mydriasis, increased intraocular pressure. <span class="typehead">CNS:</span> Drowsiness. <span class="typehead">Urogenital:</span> Decreased sexual activity, difficult urination. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Decreased absorption of <b>ketoconazole;</b> <span class="classification">oral potassium</span> may increase risk of GI ulcers; <span class="typehead">Food:</span> Food significantly decreases absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract. <span class="typehead">Onset:</span> 3045 min. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Metabolism:</span> 50% metabolized in GI tract before absorption; 50% metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine; some excreted in bile. <span class="typehead">Half-Life:</span> 9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess bowel sounds, especially in presence of ulcerative colitis, since paralytic ileus may develop, predisposing to toxic
            megacolon.
         </li>
<li>Be aware that older adult or debilitated patients may respond to a usual dose with agitation, excitement, confusion, drowsiness.
            Stop drug and report to physician if these symptoms are observed.
         </li>
<li>Check BP, heart sounds and rhythm periodically in patients with cardiac disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Void just prior to each dose to minimize risk of urinary hesitancy or retention. Record daily urinary volume and report problems
            to physician.
         </li>
<li>Relieve dry mouth by rinsing with water frequently, chewing sugar-free gum or sucking hard candy.</li>
<li>Maintain adequate fluid and high-fiber food intake to prevent constipation.</li>
<li>Make all position changes slowly and lie down immediately if faintness, weakness, or palpitations occur. Report symptoms to
            physician.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>